Ardelyx (ARDX) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Ardelyx (ARDX) Reports In-Line Q4 EPS

Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results

February 17, 2017 4:05 PM EST

FREMONT, Calif., Feb. 17, 2017 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardiorenal and gastrointestinal (GI) diseases, today reported recent company progress and financial results for the fourth quarter and full year ended December 31, 2016.

"We're very proud of what we achieved in 2016 and have continued to build on that momentum in 2017, with a number of additional important milestones ahead of us," said Mike Raab, president and chief executive officer of Ardelyx. "The... More